Stereotaxis Announces First Pre-clinical Evaluation of a Magnetically Enabled Injection Catheter

May 16, 2006, 01:00 ET from Stereotaxis, Inc.

    ST. LOUIS, May 16 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq:
 STXS) announced today the successful completion of a proof of concept
 demonstration of a magnetically enabled endocardial injection catheter
 developed in collaboration with Biologics Delivery Systems Group, Cordis
 Corporation. This successful proof of concept demonstration was the first
 ever automated mapping and therapeutic cell injection procedure and
 represents a significant breakthrough in the future of adult
 (non-embryonic) stem cell therapy.
     The procedure, which was performed by Dr. Emerson Perin, of the Texas
 Heart Institute, St. Luke's Hospital, Houston, involved the remote magnetic
 steering of the Stereotaxis Niobe(R) Magnetic Navigation System, the
 electromechanical mapping features of the Noga XP(TM) Cardiac Navigation
 System and a uniquely designed, magnetically enabled injection catheter.
 Performing the entire procedure remotely from the control room, Dr. Perin
 mapped the left ventricle and identified and easily navigated the magnetic
 injection catheter to 15 targeted injection sites in the left ventricle. He
 was able to obtain excellent injection delivery, including delivery to the
 most challenging ventricular locations.
     "Based on my previous experiences, the combination of these two
 advanced technologies has the potential to become the new gold standard for
 precise, safe and rapid injection of adult stem cells and other therapies
 into the heart," said Dr. Perin. "I look forward to working with
 Stereotaxis and Biologics Delivery Systems in the continued development of
 this technology."
     Stereotaxis believes its magnetic navigation platform has the potential
 to provide dramatically faster left ventricular mapping and improved safety
 and delivery of biologics due to enhanced catheter tip control. In
 addition, the Company's magnetic platform will enable the physician to
 perform fully automated mapping and injection procedures from the control
 room.
     "The precise and safe delivery of therapeutic biologic agents
 represents a substantial market opportunity for Stereotaxis," said Bevil
 Hogg, President and CEO of Stereotaxis. "The successful completion of this
 first-of-its-kind procedure represents a significant initial milestone for
 both companies in this area."
     Dr. Perin will be presenting an update on this procedure and the role
 of the newly developed magnetically enabled remote mapping and injection
 system on May 18th at the upcoming EuroPCR 2006 conference in Paris.
     About Stereotaxis
     Stereotaxis designs, manufactures and markets an advanced cardiology
 instrument control system for use in a hospital's interventional surgical
 suite to enhance the treatment of coronary artery disease and arrhythmias.
 The Stereotaxis System is designed to enable physicians to complete more
 complex interventional procedures by providing image guided delivery of
 catheters and guidewires through the blood vessels and chambers of the
 heart to treatment sites. This is achieved using computer-controlled,
 externally applied magnetic fields that govern the motion of the working
 tip of the catheter or guidewire, resulting in improved navigation, shorter
 procedure time and reduced x-ray exposure. The core components of the
 Stereotaxis system have received regulatory clearance in the U.S., Europe
 and Canada.
     This press release includes statements that may constitute "forward-
 looking" statements, usually containing the words "believe," "estimate,"
 "project," "expect" or similar expressions. Forward-looking statements
 inherently involve risks and uncertainties that could cause actual results
 to differ materially from the forward-looking statements. Factors that
 would cause or contribute to such differences include, but are not limited
 to, continued acceptance of the Company's products in the marketplace,
 competitive factors, changes in government reimbursement procedures,
 dependence upon third-party vendors, and other risks discussed in the
 Company's periodic and other filings with the Securities and Exchange
 Commission. By making these forward-looking statements, the Company
 undertakes no obligation to update these statements for revisions or
 changes after the date of this release. There can be no assurance that we
 will recognize revenue related to our purchase orders and other commitments
 in any particular period or at all because some of these purchase orders
 and other commitments are subject to contingencies that are outside of our
 control. In addition, these orders and commitments may be revised, modified
 or canceled, either by their express terms, as a result of negotiations, or
 by project changes or delays.
     Contacts:
 
     Stereotaxis, Inc.                    Noonan Russo
     314-678-6105                         212-845-4269
     Jim Stolze, Chief Financial Officer  Brian Ritchie (investors)
     jstolze@stereotaxis.com              brian.ritchie@eurorscg.com
 
 

SOURCE Stereotaxis, Inc.
    ST. LOUIS, May 16 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq:
 STXS) announced today the successful completion of a proof of concept
 demonstration of a magnetically enabled endocardial injection catheter
 developed in collaboration with Biologics Delivery Systems Group, Cordis
 Corporation. This successful proof of concept demonstration was the first
 ever automated mapping and therapeutic cell injection procedure and
 represents a significant breakthrough in the future of adult
 (non-embryonic) stem cell therapy.
     The procedure, which was performed by Dr. Emerson Perin, of the Texas
 Heart Institute, St. Luke's Hospital, Houston, involved the remote magnetic
 steering of the Stereotaxis Niobe(R) Magnetic Navigation System, the
 electromechanical mapping features of the Noga XP(TM) Cardiac Navigation
 System and a uniquely designed, magnetically enabled injection catheter.
 Performing the entire procedure remotely from the control room, Dr. Perin
 mapped the left ventricle and identified and easily navigated the magnetic
 injection catheter to 15 targeted injection sites in the left ventricle. He
 was able to obtain excellent injection delivery, including delivery to the
 most challenging ventricular locations.
     "Based on my previous experiences, the combination of these two
 advanced technologies has the potential to become the new gold standard for
 precise, safe and rapid injection of adult stem cells and other therapies
 into the heart," said Dr. Perin. "I look forward to working with
 Stereotaxis and Biologics Delivery Systems in the continued development of
 this technology."
     Stereotaxis believes its magnetic navigation platform has the potential
 to provide dramatically faster left ventricular mapping and improved safety
 and delivery of biologics due to enhanced catheter tip control. In
 addition, the Company's magnetic platform will enable the physician to
 perform fully automated mapping and injection procedures from the control
 room.
     "The precise and safe delivery of therapeutic biologic agents
 represents a substantial market opportunity for Stereotaxis," said Bevil
 Hogg, President and CEO of Stereotaxis. "The successful completion of this
 first-of-its-kind procedure represents a significant initial milestone for
 both companies in this area."
     Dr. Perin will be presenting an update on this procedure and the role
 of the newly developed magnetically enabled remote mapping and injection
 system on May 18th at the upcoming EuroPCR 2006 conference in Paris.
     About Stereotaxis
     Stereotaxis designs, manufactures and markets an advanced cardiology
 instrument control system for use in a hospital's interventional surgical
 suite to enhance the treatment of coronary artery disease and arrhythmias.
 The Stereotaxis System is designed to enable physicians to complete more
 complex interventional procedures by providing image guided delivery of
 catheters and guidewires through the blood vessels and chambers of the
 heart to treatment sites. This is achieved using computer-controlled,
 externally applied magnetic fields that govern the motion of the working
 tip of the catheter or guidewire, resulting in improved navigation, shorter
 procedure time and reduced x-ray exposure. The core components of the
 Stereotaxis system have received regulatory clearance in the U.S., Europe
 and Canada.
     This press release includes statements that may constitute "forward-
 looking" statements, usually containing the words "believe," "estimate,"
 "project," "expect" or similar expressions. Forward-looking statements
 inherently involve risks and uncertainties that could cause actual results
 to differ materially from the forward-looking statements. Factors that
 would cause or contribute to such differences include, but are not limited
 to, continued acceptance of the Company's products in the marketplace,
 competitive factors, changes in government reimbursement procedures,
 dependence upon third-party vendors, and other risks discussed in the
 Company's periodic and other filings with the Securities and Exchange
 Commission. By making these forward-looking statements, the Company
 undertakes no obligation to update these statements for revisions or
 changes after the date of this release. There can be no assurance that we
 will recognize revenue related to our purchase orders and other commitments
 in any particular period or at all because some of these purchase orders
 and other commitments are subject to contingencies that are outside of our
 control. In addition, these orders and commitments may be revised, modified
 or canceled, either by their express terms, as a result of negotiations, or
 by project changes or delays.
     Contacts:
 
     Stereotaxis, Inc.                    Noonan Russo
     314-678-6105                         212-845-4269
     Jim Stolze, Chief Financial Officer  Brian Ritchie (investors)
     jstolze@stereotaxis.com              brian.ritchie@eurorscg.com
 
 SOURCE Stereotaxis, Inc.